Virax Biolabs Group Statistics

NASDAQ: VRAXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

2.11+0.08 (+3.94%)

At close: Oct 7, 4:00 PM ET · Delayed 15 min

Virax Biolabs Group by the numbers

Virax Biolabs Group has a market capitalization of $2.8 million based on 1.34M shares outstanding. With trailing EPS of $-13.40, Virax Biolabs Group is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 21.5% below its 50-day average and 54.1% below its 200-day average.

Average daily trading volume is 1.80M shares, or about $3.8 million in dollar volume.

Summary generated from market data by MetaCap's automated system. Methodology

VRAX valuation vs. peer median

VRAX compared with the median of 8 peer companies
Metric	VRAX	Peer median	Difference
Market cap	$2.84M	$7.79M	-64%
Avg. volume	1.80M	152.93K	+1076%

Peer median across 8 companies: QCLS, TRIB, CDIO, VNRX, BMRA, ICCC, IMDX, NTLA.

Valuation

Market cap: $2.84M
P/E (TTM): —
Forward P/E: —
EPS (TTM): $-13.40
Shares outstanding: 1.34M

Price and trading

Previous close: 2.03
Open: 2.02
Day range: 1.83 – 2.18
52-week range: 1.83 – 21.75
50-day moving average: 2.69
200-day moving average: 4.60
Beta: —
Volume: 265.35K
Average volume: 1.80M

Dividends and events

Annual dividend: None
Dividend yield: —
Ex-dividend date: —
Next earnings date: —

Additional statistics

Market Cap: 2.84M
Forward Pe: -0.35
Eps: -13.40
Dividend Yield: 0.00%
Dividend Rate: 0.00
Week52 High: 21.75
Week52 Low: 1.83
Avg Volume: 1.80M
Shares Outstanding: 1.34M
Ma50: 2.69
Ma200: 4.60
Pct From52w High: -90.30%
Pct From52w Low: 15.30%